Literature DB >> 6354808

Alpha-1-antitrypsin MZ phenotype and cryptogenic chronic liver disease in adults.

F M Vecchio, A Fabiano, G Orsini, D Ragusa, G Massi.   

Abstract

Intrahepatocytic inclusions of alpha-1-antitrypsin as markers of Z allele were searched by histochemical and immunohistochemical (peroxidase-antiperoxidase) methods in needle biopsy specimens from 80 consecutive cases of cryptogenic cirrhosis and chronic active hepatitis - HBsAg-negative - in adults. All positive cases and 26% of the negative ones were phenotyped in order to determine the frequency of heterozygous (MZ) deficiency. At variance with previous studies, no prevalence of heterozygous (MZ) deficiency could be demonstrated. This result indicates that further investigations are mandatory to establish if heterozygous (MZ) subjects are predisposed to chronic liver disease.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6354808     DOI: 10.1159/000198937

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  5 in total

Review 1.  Cryptogenic chronic hepatitis and its changing guise in adults.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2011-06-07       Impact factor: 3.199

2.  Frequency and significance of phenotypes for alpha1-antitrypsin deficiency in type 1 autoimmune hepatitis.

Authors:  A J Czaja
Journal:  Dig Dis Sci       Date:  1998-08       Impact factor: 3.199

3.  Serum levels of alpha1-antitrypsin predict phenotypic expression of the alpha1-antitrypsin gene.

Authors:  Steven J Steiner; Sandeep K Gupta; Joseph M Croffie; Joseph F Fitzgerald
Journal:  Dig Dis Sci       Date:  2003-09       Impact factor: 3.199

4.  Heterozygosity of the Alpha 1-Antitrypsin Pi*Z Allele and Risk of Liver Disease.

Authors:  Aaron Hakim; Matthew Moll; Dandi Qiao; Jiangyuan Liu; Jessica A Lasky-Su; Edwin K Silverman; Silvia Vilarinho; Z Gordon Jiang; Brian D Hobbs; Michael H Cho
Journal:  Hepatol Commun       Date:  2021-04-03

5.  Alpha-1-antitrypsin phenotypes in adult liver disease patients.

Authors:  Aleksandra Topic; Tamara Alempijevic; Aleksandra Sokic Milutinovic; Nada Kovacevic
Journal:  Ups J Med Sci       Date:  2009       Impact factor: 2.384

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.